Literature DB >> 300399

Generation of cytotoxic T lymphocytes during coxsackievirus B-3 infection. I. Model and viral specificity1.

C Y Wong, J J Woodruff, J F Woodruff.   

Abstract

The production of cytotoxic cells in the spleen of adult male BALB/c mice infected with Coxsackievirus B-3 has been examined. An in vitro 51Cr release assay was used to measure cytotoxic activity against virus-infected and uninfected neonatal sygeneic fibroblasts. Cytotoxicity of immune spleen cells against virus-infected targets was detected on the 3rd day after infection, reached a peak on day 7, and then declined to low levels by days 12 and 14. Spleen cells obtained 3 and 5 days after infection also exerted cytotoxicity against uninfected fibroblasts, but by the 7th day there was little or no reactivity against uninfected target cells, although activity against infected fibroblasts was maximal at this time. Reciprocal assays performed by using Coxsackie and vaccinia viruses provided evidence of virus specificity of the cytotoxic reaction. When spleen cells were obtained 7 days after infection, the Coxsackievirus-immune population was not cytotoxic for vaccinia-infected fibroblasts, and the vaccinia-immune population was not cytotoxic for Coxsackievirus-infected targets, although each immune cell preparation caused significant lysis of fibroblasts infected with the homologous virus. Additional studies showed that primary mouse or hyperimmune rabbit anti-Coxsackieviral serum could not block immune spleen cell cytotoxicity or induce complement-mediated lysis of infected targets. The findings indicate that Coxsackievirus infection results in surface membrane alterations, but no evidence was obtained that antiviral antibody could react with the infected cells.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 300399

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

Review 1.  Cardiac myosin and the TH1/TH2 paradigm in autoimmune myocarditis.

Authors:  M W Cunningham
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Antibodies to Coxsackie B viruses in congestive cardiomyopathy.

Authors:  G Cambridge; C G MacArthur; A P Waterson; J F Goodwin; C M Oakley
Journal:  Br Heart J       Date:  1979-06

Review 3.  Coxsackievirus infection as a trigger of cardiac autoimmunity.

Authors:  L J Wolfgram; N R Rose
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

4.  In situ immune autoradiographic identification of cells in heart tissues of mice with coxsackievirus B3-induced myocarditis.

Authors:  E K Godeny; C J Gauntt
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

5.  Cytotoxic T lymphocytes and natural killer cell activity in the course of mengo virus infection of mice.

Authors:  D Hassin; R Fixler; H Bank; A S Klein; Y Hasin
Journal:  Immunology       Date:  1985-12       Impact factor: 7.397

6.  Assessment of coxsackievirus B3 ts mutants for induction of myocarditis in a murine model.

Authors:  M D Trousdale; R E Paque; T Nealon; C J Gauntt
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

7.  The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis.

Authors:  A Henke; S Huber; A Stelzner; J L Whitton
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 8.  Myocardial diseases of animals.

Authors:  J F Van Vleet; V J Ferrans
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

9.  Temperature-sensitive mutant of coxsackievirus B3 establishes resistance in neonatal mice that protects them during adolescence against coxsackievirus B3-induced myocarditis.

Authors:  C J Gauntt; R E Paque; M D Trousdale; R J Gudvangen; D T Barr; G J Lipotich; T J Nealon; P S Duffey
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

10.  Diagnostic relevance of humoral and cell-mediated immune reactions in patients with acute viral myocarditis.

Authors:  B Maisch; R Trostel-Soeder; E Stechemesser; P A Berg; K Kochsiek
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.